144 related articles for article (PubMed ID: 29201766)
41. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
[TBL] [Abstract][Full Text] [Related]
42. Dual vs. triple therapy for childhood Helicobacter pylori gastritis: a double-blind randomized multicentre trial.
Oderda G; Marinello D; Lerro P; Kuvidi M; de'Angelis GL; Ferzetti A; Cucchiara S; Franco MT; Romano C; Strisciuglio P; Pensabene L
Helicobacter; 2004 Aug; 9(4):293-301. PubMed ID: 15270743
[TBL] [Abstract][Full Text] [Related]
43. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Greenberg ER; Anderson GL; Morgan DR; Torres J; Chey WD; Bravo LE; Dominguez RL; Ferreccio C; Herrero R; Lazcano-Ponce EC; Meza-Montenegro MM; Peña R; Peña EM; Salazar-Martínez E; Correa P; Martínez ME; Valdivieso M; Goodman GE; Crowley JJ; Baker LH
Lancet; 2011 Aug; 378(9790):507-14. PubMed ID: 21777974
[TBL] [Abstract][Full Text] [Related]
44. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
45. Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection.
Demirci H; Uygun İlikhan S; Öztürk K; Üstündağ Y; Kurt Ö; Bilici M; Köktürk F; Uygun A
Turk J Gastroenterol; 2015 Nov; 26(6):456-60. PubMed ID: 26510082
[TBL] [Abstract][Full Text] [Related]
46. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.
Rakici H; Ayaz T; Akdogan RA; Bedir R
Digestion; 2014; 90(4):261-4. PubMed ID: 25547786
[TBL] [Abstract][Full Text] [Related]
47. Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate.
Ojetti V; Migneco A; Zocco MA; Nista EC; Gasbarrini G; Gasbarrini A
J Intern Med; 2004 Jan; 255(1):125-9. PubMed ID: 14687248
[TBL] [Abstract][Full Text] [Related]
48. Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.
Wong BC; Xiao SD; Hu FL; Qian SC; Huang NX; Li YY; Hu PJ; Daldiyono ; Manan C; Lesmana L; Carpio RE; Perez JY; Fock KM; Kachintorn U; Phornphutkul K; Kullavanijaya P; Ho J; Lam SK
Aliment Pharmacol Ther; 2000 Feb; 14(2):217-24. PubMed ID: 10651663
[TBL] [Abstract][Full Text] [Related]
49. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?
Hung IF; Chan P; Leung S; Chan FS; Hsu A; But D; Seto WK; Wong SY; Chan CK; Gu Q; Tong TS; Cheung TK; Chu KM; Wong BC
Helicobacter; 2009 Dec; 14(6):505-11. PubMed ID: 19889067
[TBL] [Abstract][Full Text] [Related]
50. Comparison of sequential and standard therapy for Helicobacter pylori eradication in children and investigation of clarithromycin resistance.
Erdur B; Ozturk Y; Gurbuz ED; Yilmaz O
J Pediatr Gastroenterol Nutr; 2012 Nov; 55(5):530-3. PubMed ID: 22465935
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy.
Togawa J; Inamori M; Fujisawa N; Takahashi H; Yoneda M; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
Hepatogastroenterology; 2005; 52(62):645-8. PubMed ID: 15816496
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials.
Fang HR; Zhang GQ; Cheng JY; Li ZY
Eur J Pediatr; 2019 Jan; 178(1):7-16. PubMed ID: 30446816
[TBL] [Abstract][Full Text] [Related]
53. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy.
Huang AH; Sheu BS; Yang HB; Huang CC; Wu JJ; Lin XZ
J Formos Med Assoc; 2000 Sep; 99(9):704-9. PubMed ID: 11000734
[TBL] [Abstract][Full Text] [Related]
54. Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial.
Lee H; Kim BJ; Kim SG; Kim JI; Choi IJ; Lee YC; Kim JG; Kim JJ;
Trials; 2017 Nov; 18(1):549. PubMed ID: 29149904
[TBL] [Abstract][Full Text] [Related]
55. Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India.
Bhasin DK; Sharma BC; Ray P; Pathak CM; Singh K
Helicobacter; 2000 Jun; 5(2):84-7. PubMed ID: 10849056
[TBL] [Abstract][Full Text] [Related]
56. Influence of adding vitamin D3 to standard clarithromycin-based triple therapy on the eradication rates of Helicobacter pylori infection.
El Shahawy MS; Shady ZM; Gaafar A
Arab J Gastroenterol; 2021 Sep; 22(3):209-214. PubMed ID: 34521593
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection.
Du YQ; Su T; Fan JG; Lu YX; Zheng P; Li XH; Guo CY; Xu P; Gong YF; Li ZS
World J Gastroenterol; 2012 Nov; 18(43):6302-7. PubMed ID: 23180952
[TBL] [Abstract][Full Text] [Related]
58. The efficacy of sequential therapy in eradication of
Harmandar F; İlikhan SU; Üstüündağn Y; Harmandar O
Niger J Clin Pract; 2017 May; 20(5):616-621. PubMed ID: 28513523
[TBL] [Abstract][Full Text] [Related]
59. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.
Navarro-Rodriguez T; Silva FM; Barbuti RC; Mattar R; Moraes-Filho JP; de Oliveira MN; Bogsan CS; Chinzon D; Eisig JN
BMC Gastroenterol; 2013 Mar; 13():56. PubMed ID: 23530767
[TBL] [Abstract][Full Text] [Related]
60. Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection.
Hagiwara T; Kato M; Anbo T; Imamura A; Suga T; Uchida T; Fujinaga A; Nakagawa M; Nakagawa S; Shimizu Y; Yamamoto J; Takeda H; Asaka M
World J Gastroenterol; 2007 Jul; 13(28):3836-40. PubMed ID: 17657838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
